$3.34
+0.09 (+2.77%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ICU is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 observational · 2 with posted results
Held by 1 tracked-famous manager (JANE STREET GROUP, LLC) · FINRA short interest 1.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVADNCT03836482Need for continuous IV vasopressor supportOpen-label · Treatment | Not applicable | Recruiting | Device: Selective Cytopheretic Device | Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome | 20 | Feb 2027 | ≤ 193 d | 2026-03-31 |
| Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney InjuryNCT05758077Composite endpoint of mortality or dialysis dependency at 90 daysRandomized · Open-label · Treatment | Not applicable | Recruiting | Device: Selective Cytopheretic Device · Other: Standard of Care | Acute Kidney Injury | 339 | Dec 2026 | ≤ 134 d | 2026-04-23 |
| QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistryNCT06517810observationalSafety | — | Recruiting | Device: QUELIMMUNE (SCD-PED) | Acute Kidney Injury, Acute Kidney Injury Due to Sepsis | 50 | May 2026 | — | 2026-05-14 |
| Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 InfectionsNCT04395911Mortality at Day 60Open-label · Treatment | Not applicable | Completed | Device: SCD | AKI, ARDS, COVID | 22 | 2021-07-05actual | — | 2021-08-05 |
| C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19NCT04537975Pulmonary Oxygenation FunctionRandomized · Open-label · Treatment | Not applicable | Withdrawnsponsor's stated reason: Withdrawn (Study was withdrawn by Sponsor because of change in regulatory strategy.) | Device: C2Rx · Other: Standard of Care (SOC) | Continuous Renal Replacement Therapy, Pulmonary Edema, COVID-19 | 0 | 2020-11-15 | — | 2020-12-14 |
| Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney InjuryNCT01400893results2017-08-29The Primary Clinical Efficacy Endpoint in This Trial is All Cause Mortality Through 60 Days Post-randomization.Randomized · Open-label · Treatment | Not applicable | Terminated | Device: SCD | Acute Kidney Injury | 134 | Sep 2013actual | — | 2021-04-27 |
| Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal FailureNCT01072682results2022-03-0960 Day MortalityOpen-label · Treatment | Not applicable | Completed | Device: Selective cytopheretic device (SCD) | Acute Renal Failure | 35 | May 2011actual | — | 2022-03-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19